Sincerus Florida, LLC

SKNV Licenses Washington University Immunotherapy Patent for Fluorouracil-Calcipotriene Combination in Actinic Keratosis

- SKNV has licensed a Washington University patent portfolio covering the fluorouracil-calcipotriene combination therapy for actinic keratosis, moving academic immunotherapy research into commercial practice through the compounding market. - The American Academy of Dermatology has updated its guidance to favor field-directed therapy over lesion-by-lesion treatment, with the combination central to this shift due to its potential to reduce progression to squamous cell carcinoma. - Published data in the Journal of Clinical Investigation showed the combination reduced AK lesion counts after just four days of treatment, compared to the two-to-four-week course required for fluorouracil monotherapy. - A follow-up study tracking patients for over 1,500 days linked the short-course combination therapy to reduced squamous cell carcinoma incidence, an effect associated with persistence of tissue-resident memory T cells.